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Lionnet et al.
1
 recently reported a high prevalence of retinopathy (RET) and otologic 
disorders (OTD) in patients with sickle cell-hemoglobin C disease (SC), while a significant 
number of patients had renal diseases (mainly glomerulopathy; GLO) and osteonecrosis 
(OST). The pathophysiological processes of these complications in SC are not well defined, 
although blood hyperviscosity has been suspected, but never tested to the best of our 
knowledge, as responsible for several chronic complications in SC disease
1,2
.The aim of this 
study was to analyze the associations between hematological and hemorheological parameters 
and chronic complications in adult SC patients. 
 
Ninety consecutive adults with SC (M/F: 40/50; mean age: 38 ± 13 yr)were enrolled in the 
study. All patients were at steady state at study entry, i.e., no phlebotomy orblood transfusions 
in the previous three months, and absence of acute episodes (infection, vaso-occlusive crisis 
(VOC), acute chest syndrome (ACS), stroke, priapism) at least three months before 
enrollment. Pregnancy or breast feeding were also exclusion criteria. The study was 
conducted in accordance to the Declaration of Helsinki, and approved by the Regional Ethics 
Committee (registration number: 2010-A00244-35). Written informed consent was obtained 
from all participants. 
History, presence of chronic disorders, and acute event occurrence during the previous year of 
study were obtained from retrospective chart review by two physicians.Patients under regular 
phlebotomy protocols, but without any phlebotomy in the 3 months preceding the study were 
identified. Phlebotomyis usually performed in symptomatic SC patientsto avoid recurrent 
acute events3,and has been prescribedby some when hemoglobin and/or hematocrit rise above 
11 g/dL or 32%, respectively,to prevent complications with suspected blood hyperviscosity1,4. 
The optimal target hemoglobin level to reach under phlebotomy is unknown but our Sickle 
Cell Centre usually tries to reduce hemoglobin to 9.5-10.5 g/dL.In our study, SC patients with 
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values greater than 11g/dL and 32% but no clinical assessment of blood viscosity were 
categorized as having “theoreticalhyperviscosity”.  
Measurements of hematological and hemolytic parameters (bilirubin, lactate dehydrogenase, 
aspartate aminotransferase) were performed using standard methods5.Blood viscosity, red 
blood cell (RBC) deformability, aggregation and disaggregation threshold (i.e., RBC 
aggregates strength) were measured as described6,7.   
Unpaired Student’s t-test and chi-square or Kappa coefficient test were used for continuous 
and categorical covariates, respectively. Association between several parameters was tested 
by Pearson correlation. The hemolytic component value was derived from hemolytic markers  
(bilirubin, lactate dehydrogenase, aspartate aminotransferase and reticulocytes) by principal 
component analysis8. 
 
The most prevalent chronic complications in our SC cohort were RET (60%), GLO (micro-
/macro-albuminuria, 40%), OST (31%), and OTD (20%). Leg ulcers, pulmonary hypertension 
and cerebral vasculopathy/stroke were extremely rare (2% each), as were ACS (2%) and VOC 
(5%) during the study period.Few males (8%) had a history of priapism.  
 
Patients with OTD (OTD+) had higher RBC count (p<0.05), and a tendency to higher 
hemoglobin level than patients without OTD (OTD-; p<0.1; Table 1). Blood viscosity was 
increased by 9.1% in OTD+ compared to OTD- patients (p<0.05). SC RET+ patients had 
lower RBC deformability than RET- (p<0.05; Table 1). No association was observed between 
hematological or hemorheological parameters and OST or GLO. Nevertheless, OST+ and 
GLO+ patients were older than OST- and GLO- individuals (p<0.001 and p<0.01, 
respectively).An association was found between RET and OST, with higher frequency of 
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OST+ in the RET+ (38%) than in the RET- (18%; p<0.05) groups. No association was found 
between the other complications. 
In our cohort, 43% SC patients underwent phlebotomy, 74% of them on a regular basis (every 
3 months). The frequency of RET+ and RET- patients treated by phlebotomy was not 
different, as 57.6% RET+ patients had phlebotomy vs. 42.4% RET- patients. Only a trend 
towards greater phlebotomy use was observed in OTD+ patients (64%; p<0.1). Most patients 
(88.6%) with “theoreticalhyperviscosity” (hemoglobin>11g/dL/hematocrit>32%)were 
phlebotomized (p<0.01). Comparing patients with or without theoreticalhyperviscosity 
demonstrated no significant difference in blood viscosity (7.50±1.03 vs 7.22±.35 cP, 
respectively), whilehemoglobin and hematocritwere higher in the 
theoreticalhyperviscositygroup (11.8±1.0 vs 11.2±1.3 g/dL and 32.3±2.5 vs 30.6±3.2 %, 
respectively; p<0.01), as expected. Thecohort was divided according to the median measured 
viscosity, and patients with blood viscositygreater than median value were considered as 
having“true hyperviscosity”.No significant association was found between theoreticaland 
truehyperviscosity (Kappa coefficient=0.09), or between blood viscosity and hemoglobin or 
hematocrit, (r=0.19 and r=0.18, respectively; p=0.16 in both cases). 
 
Elevated blood viscosity was hypothesized to cause ischemia at the labyrinthine artery level, 
leading to cochlear damage9.This is in agreement with our cohort where OTD+ patients had 
higher blood viscosity than OTD-. However, OTD+ had only a trend towards higher 
hemoglobin and similar hematocrit as OTD-.  Blood viscosity is influenced by several factors, 
including hematocrit and hemoglobin, hence their clinical use to prescribe phlebotomy. 
However, this relationship was not significant in our cohort. Blood viscosity depends also on 
the rheological properties of RBCs: i.e., deformability and aggregation. For a given 
hemoglobin level, increased RBC deformability lowers blood viscosity while increased RBC 
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aggregation causes a rise. The complex contribution of each hemorheological factor on blood 
viscosity makes that blood viscosity may be elevated in some patients despite “normal” 
hematocrit and hemoglobin levels. 
More importantly, most patients with “theoretical hyperviscosity” did not have high blood 
viscosity, and only 44% of patients with measured “true hyperviscosity” were phlebotomized. 
Thus, as periodic phlebotomy could be useful to decrease blood viscosity in hyperviscous SC 
patients as it is in patients with polycythemia vera
10
 or cyanotic congenital heart disease
11
, our 
findings strongly suggest that blood viscosity measurements would allow better identification 
of SC patients at risk for OTD. 
In contrast to OTD, RET was not associated with blood hyperviscosity. Instead, RBC 
deformability was decreased by 10% in RET+ compared to RET- patients. RBC deformability 
is critical for optimal tissue perfusion and adequate blood flow in the micro-/ macro-
circulation12, and reduced RBC deformability is associated with diabetic retinopathy13,14. The 
effects of phlebotomy on RBC deformability in SC patients with RET have never been 
investigated, calling for further studies to address this question. 
In conclusion, our study provides new data on the pathophysiology of several frequent 
chronic complications in SC disease. They clearly show that the clinical use of 
hemoglobinand hematocrit as surrogates for high blood viscosityin SC patients is not 
satisfactory for establishing treatment or determining risk for OTD. A prospective study to 
evaluate the relationships between blood rheology and the occurrence of acute complications 
iswarranted.   
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Table 1: Hematological and hemorheological determinants of otologic disorders, retinopathy, osteonecrosis and glomerulopathy in SC patients. 
 Otologic disorders (OTD) Retinopathy (RET) Osteonecrosis (OST) Glomerulopathy (GLO) 
 OTD- 
(n = 64) 
OTD+ 
(n = 16) 
RET- 
(n = 33) 
RET+ 
(n = 49) 
OST- 
(n = 62) 
OST+ 
(n = 28) 
GLO- 
(n = 51) 
GLO+ 
(n = 34) 
Age (years) 40 ± 13 37 ± 14 39 ± 14 39 ± 13 35 ± 12 45 ± 13*** 36 ± 13 43 ± 13** 
White blood cells (x10
9
L) 7.4 ± 2.6 7.0 ± 2.4 7.4 ± 2.4 7.4 ± 2.6 7.6 ± 3.0 7.0 ± 2.4 7.4 ± 2.9 7.6 ± 2.4 
Platelet count (x10
9
L) 306 ± 154 292 ± 151 298 ± 166 302 ± 145 308 ± 156 278 ± 139 301 ± 152 308 ± 152 
Red blood cells (x10
12
L) 4.3 ± 0.6 4.7 ± 0.7* 4.3 ± 0.7 4.4 ± 0.7 4.4 ± 0.7 4.4 ± 0.6 4.4 ± 0.6 4.3 ± 0.6 
Hemoglobin (g/dL) 11.2 ± 1.1 11.8 ± 1.3
$
 11.3 ± 1.2 11.4 ± 1.2 11.4 ±1.3 11.3 ± 1.1 11.5 ± 1.1 11.2 ± 1.2 
Hematocrit (%) 31.0 ± 2.7 32.1 ± 3.8 31.0 ± 2.9 31.3 ± 3.1 31.1 ± 3.2 31.4 ± 2.9 31.4 ± 2.8 30.8 ± 3.1 
Hemolytic index (relative unit) 0.01 ± 0.98 -0.21 ± 0.96 -0.12 ± 1.07 0.02 ± 0.93 0.02 ± 0.99 -0.03 ± 1.03 -0.06 ± 0.94 0.08 ± 1.08 
Blood viscosity (cP) 7.38 ± 1.17 8.10 ± 0.85* 7.60 ± 1.10 7.28 ± 1.32 7.40 ± 1.14 7.50 ± 1.42 7.51 ±1.22 7.34 ± 1.16 
RBC deformability (a.u) 0.43 ± 0.07 0.41 ± 0.06 0.45 ± 0.06 0.41 ± 0.05* 0.43 ± 0.07 0.42 ±0.07 0.42 ± 0.07 0.43 ± 0.07 
RBC aggregation (%) 49 ± 8 47 ± 11 50 ± 8 48 ± 10 47 ± 8 50 ± 10 47 ± 10 50 ± 8 
RBC disaggregation threshold (s
-1
) 320 ± 126 312 ± 132 317 ± 101 319 ± 140 306 ± 115 330 ± 141 312 ± 144 314 ± 91 
Means ± SD. - = absence of complication and + = presence of complication.Sensorineural OTD (requiring hospitalization or not) were recorded 
using previously defined criteria1. Criteria used to define VOC and ACS events (within the previous year of study) were similar to those used in 
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previous studies performed in SCA adults7.Criteria used to define osteonecrosis and glomerulopathy were similar to those used in previous 
studies5,15.Difference between groups (*p<0.05; **p<0.01; ***p<0.001).$Statistical trend (p<0.1). 
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